IMM Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): A$0.00
Insider Selling (Last 12 Months): A$0.00

Immutep Insider Trading History Chart

This chart shows the insider buying and selling history at Immutep by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immutep Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for IMM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
🚨 [Strong Buy Alert] Is this laser stock in your portfolio?
There are very few opportunities like this in today's bear market...

But our analysts identified a tiny defense company landing billions of dollars in contracts every year.
Get the name of the company here >>>

Immutep Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/3/2022Frederic TriebelInsiderExercise900,000A$0.24A$216,000.00
12/1/2021Russell HowardInsiderExercise250,000A$0.48A$118,750.00
10/4/2021Pete MeyersInsiderExercise500,000A$0.54A$267,500.00
11/6/2020Grant ChamberlainInsiderIssued1,350,000A$0.29A$391,500.00
10/2/2020Pete MeyersInsiderBuy273,637A$0.24A$64,304.70
3/16/2020Grant ChamberlainInsiderBuy360,623A$0.28A$99,892.57
1/2/2020Marc VoigtInsiderIssued1,666,667A$0.26A$433,333.42
See Full Table

SEC Filings (Institutional Ownership Changes) for Immutep (ASX:IMM)

Immutep logo
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemo-immunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is headquartered in Sydney, Australia.
Read More on Immutep

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


2,151,332 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Immutep?

Immutep's top insider investors include:
  1. Frederic Triebel (Insider)
  2. Pete Meyers (Insider)
  3. Russell Howard (Insider)
Learn More about top insider investors at Immutep.